These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

248 related articles for article (PubMed ID: 17553392)

  • 1. [Effect of incretin hormones GIP and GLP-1 for the pathogenesis of type 2 diabetes mellitus].
    Vilsbøll T; Knop FK
    Ugeskr Laeger; 2007 May; 169(22):2101-5. PubMed ID: 17553392
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Incretins, insulin secretion and Type 2 diabetes mellitus.
    Vilsbøll T; Holst JJ
    Diabetologia; 2004 Mar; 47(3):357-366. PubMed ID: 14968296
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Incretin hormones and type 2 diabetes.
    Nauck MA; Müller TD
    Diabetologia; 2023 Oct; 66(10):1780-1795. PubMed ID: 37430117
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes.
    Nauck MA; Baller B; Meier JJ
    Diabetes; 2004 Dec; 53 Suppl 3():S190-6. PubMed ID: 15561910
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incretin hormones: Their role in health and disease.
    Nauck MA; Meier JJ
    Diabetes Obes Metab; 2018 Feb; 20 Suppl 1():5-21. PubMed ID: 29364588
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Glucose-dependent insulinotropic polypeptide: effects on insulin and glucagon secretion in humans.
    Christensen MB
    Dan Med J; 2016 Apr; 63(4):. PubMed ID: 27034187
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Incretin dysfunction in type 2 diabetes: clinical impact and future perspectives.
    Ahrén B
    Diabetes Metab; 2013 May; 39(3):195-201. PubMed ID: 23643349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastric inhibitory polypeptide analogues: do they have a therapeutic role in diabetes mellitus similar to that of glucagon-like Peptide-1?
    Holst JJ
    BioDrugs; 2002; 16(3):175-81. PubMed ID: 12102645
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Secretion of incretin hormones (GIP and GLP-1) and incretin effect after oral glucose in first-degree relatives of patients with type 2 diabetes.
    Nauck MA; El-Ouaghlidi A; Gabrys B; Hücking K; Holst JJ; Deacon CF; Gallwitz B; Schmidt WE; Meier JJ
    Regul Pept; 2004 Nov; 122(3):209-17. PubMed ID: 15491793
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of chronic exposure of clonal β-cells to elevated glucose and free fatty acids on incretin receptor gene expression and secretory responses to GIP and GLP-1.
    Pathak V; Vasu S; Flatt PR; Irwin N
    Diabetes Obes Metab; 2014 Apr; 16(4):357-65. PubMed ID: 24164718
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretins and the development of type 2 diabetes.
    Meier JJ; Nauck MA
    Curr Diab Rep; 2006 Jun; 6(3):194-201. PubMed ID: 16898571
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Incretin secretion in relation to meal size and body weight in healthy subjects and people with type 1 and type 2 diabetes mellitus.
    Vilsbøll T; Krarup T; Sonne J; Madsbad S; Vølund A; Juul AG; Holst JJ
    J Clin Endocrinol Metab; 2003 Jun; 88(6):2706-13. PubMed ID: 12788877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans.
    Holst JJ; Gromada J
    Am J Physiol Endocrinol Metab; 2004 Aug; 287(2):E199-206. PubMed ID: 15271645
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Two incretin hormones GLP-1 and GIP: comparison of their actions in insulin secretion and β cell preservation.
    Yabe D; Seino Y
    Prog Biophys Mol Biol; 2011 Nov; 107(2):248-56. PubMed ID: 21820006
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overview of incretin hormones.
    Efendic S; Portwood N
    Horm Metab Res; 2004; 36(11-12):742-6. PubMed ID: 15655702
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes.
    Gautier JF; Choukem SP; Girard J
    Diabetes Metab; 2008 Feb; 34 Suppl 2():S65-72. PubMed ID: 18640588
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Suppression of glucagon secretion is lower after oral glucose administration than during intravenous glucose administration in human subjects.
    Meier JJ; Deacon CF; Schmidt WE; Holst JJ; Nauck MA
    Diabetologia; 2007 Apr; 50(4):806-13. PubMed ID: 17334652
    [TBL] [Abstract][Full Text] [Related]  

  • 18. On the role of the incretin hormones GIP and GLP-1 in the pathogenesis of Type 2 diabetes mellitus.
    Vilsbøll T
    Dan Med Bull; 2004 Nov; 51(4):364-70. PubMed ID: 16009062
    [No Abstract]   [Full Text] [Related]  

  • 19. Effects of variations in duodenal glucose load on glycaemic, insulin, and incretin responses in type 2 diabetes.
    Ma J; Pilichiewicz AN; Feinle-Bisset C; Wishart JM; Jones KL; Horowitz M; Rayner CK
    Diabet Med; 2012 May; 29(5):604-8. PubMed ID: 22004512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Reduction of hepatic insulin clearance after oral glucose ingestion is not mediated by glucagon-like peptide 1 or gastric inhibitory polypeptide in humans.
    Meier JJ; Holst JJ; Schmidt WE; Nauck MA
    Am J Physiol Endocrinol Metab; 2007 Sep; 293(3):E849-56. PubMed ID: 17609256
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.